MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Ontix, the UK based next-generation infrastructure-as-a-service provider, will be launching an Open RAN pilot for neutral host in-building connectivity in a central London office building, powered by Mavenir’s MAVair solution.
The Open RAN platform will be deployed at the Ontix Data Centre in London whilst the small cell units will be deployed at an Ontix’s customer building. The solution would enable Ontix to provide indoor mobile connectivity to typical areas like multi-tenanted offices, shopping malls, stadiums, hospitals, enterprise buildings and hot spots, delivering contiguous coverage and high-speed mobile connectivity to its enterprise customers and end consumers.
Delivering high-quality mobile connectivity indoors poses significant challenges to both operators and building owners, with a range of factors including the number of people in a building, construction materials and remote locations all impacting signal strength. It is imperative that any solution must provide service for all users, irrespective of the carrier they happen to be subscribed to, by using neutral host solutions.
Ontix and Mavenir will trial the delivery of a neutral host in-building, Open Virtualised Radio Access Network (Open vRAN) to provide enhanced connectivity. This includes the delivery and integration of Open RAN compatible, software upgradable small cells for enhanced in-building coverage and capacity.
“Open RAN is changing the dynamics of how cellular solutions are designed and delivered, and this deployment is at the cutting edge of the technology in the UK,” said Patrick Bradd, Chief Executive Officer at Ontix. “We are excited to be working on this ground-breaking Open RAN pilot to deploy a neutral host architecture to demonstrate its flexibility and how the use of commoditised hardware, can help to create the next generation of in-building networks.”
“Mavenir is delighted to partner with Ontix in addressing this demand from enterprises and consumers for mobile connectivity, especially in areas with poor indoor and in-building coverage. We are confident that using this innovative vRAN solution Ontix will be able to deliver a cost effective and a higher quality network to meet this growing demand,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
The MAVair family includes Open vRAN designed with cloud-native virtualisation techniques, enabling the RAN to flex and adapt based on usage and coverage. Mavenir’s vRAN platform provides a fully scalable virtualised network architecture with open standard interfaces, providing neutral host solution providers the option of deploying radio units from different vendors. The vRAN platform uses software running on COTS (commercial off the shelf) hardware that provides cost effectiveness, more flexibility and agility to neutral host solution providers, whilst providing one architecture for many different user scenarios.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Ontix:
Ontix is a next-generation infrastructure-as-a-service provider, disrupting the business model for delivering lightning-fast connectivity wherever it is needed. Ontix makes it cheaper, easier and quicker for mobile operators and wireless network providers to add next-generation wireless networks through its turnkey solutions. Ontix is transforming the entire process for wireless network densification by investing in shared small cell infrastructure – including connectivity – and licensing this to operators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom